Celebrating Jeffrey W. Sherman, MD, FACP: 35 Years of Excellence in Clinical Research & Pharma, Horizon's Emeritus CMO

Dr. Sherman's Impact on Rare Disease Research and Patient Advocacy Leaves a Lasting Impression in the Pharmaceutical Industry



New York City, New York Jan 23, 2025 (Issuewire.com) - Deerfield, Illinois - Horizon Therapeutics, now part of Amgen, proudly acknowledges the remarkable career of Dr. Jeffrey W. Sherman, MD, FACP, who served as the Chief Medical Officer and is now Emeritus. With over 35 years of experience in clinical research and pharmaceutical development, Dr. Sherman has made significant contributions to the field, particularly in the area of rare diseases.

Dr. Sherman's journey began with a strong educational foundation, earning his Bachelor's Degree in Biology from Lake Forest College and his Medical Degree from Chicago Medical School-Rosalind Franklin University of Medicine and Science. His commitment to excellence continued at Northwestern University Feinberg School of Medicine, where he completed his internship and residency in internal medicine, ultimately serving as Chief Resident. Dr. Sherman further honed his expertise with fellowship training in infectious diseases at the University of California-San Francisco (UCSF), where he also contributed as a research associate at the Howard Hughes Medical Institute, specializing in allergy and immunology.

As a recognized Fellow of the American College of Physicians, Dr. Sherman is board-certified in both internal medicine and infectious diseases by the American Board of Internal Medicine (ABIM). His extensive experience includes key roles at renowned pharmaceutical companies such as IDM Pharma, Takeda Global Research and Development, NeoPharm, Searle/Pharmacia, and Squibb/Bristol-Myers Squibb. Throughout his career, he has played a vital role in various advisory boards and committees, including serving as the chair of the Drug Information Association (DIA) Board of Directors, where he received an Outstanding Service Award for his leadership.

In addition to his corporate contributions, Dr. Sherman has served as a liaison to the FDA Clinical Trial Transformation Initiative (CTTI) Steering Committee and has been an active member of the Board of Advisors for the Center for Information and Study on Clinical Research Participation (CISCRP). His dedication to shaping policy and advancing clinical research methodologies has made a significant impact on the industry.

Dr. Sherman's philanthropic efforts highlight his commitment to rare disease research and patient advocacy. His involvement with the Global Genes Medical and Scientific Advisory Board, as well as the National Organization for Rare Diseases (NORD) and the European Organization for Rare Diseases (EURORDIS), showcases his relentless pursuit of improving patient care and developing innovative therapies.

Reflecting on his illustrious career, Dr. Sherman attributes his success to the mentorship of esteemed colleagues such as Dr. Lewis Smith and Dr. John Alexander, as well as the unwavering support of his family. Outside of his professional endeavors, he cherishes time spent with his grandchildren, valuing the joy of family moments.

Embracing the philosophy of "never say never" and prioritizing "patients first," Dr. Sherman embodies resilience and determination in his ongoing commitment to medical innovation and advocacy. As he transitions into this new chapter, his legacy will undoubtedly inspire future generations of medical professionals and researchers.

Learn More About Dr. Jeffrey W. Sherman:

Through his findatopdoc profile, https://www.findatopdoc.com/doctor/763639-Jeffrey-Sherman-Infectious-Disease-Specialist

About FindaTopDoc.com

FindaTopDoc is a digital health information company that helps connect patients with local physicians and specialists who accept your insurance. Our goal is to help guide you on your journey towards optimal health by providing you with the know-how to make informed decisions for you and your family.

Media Contact

Your Health Contact

******@yourhealthcontact.com

Source: Dr. Jeffrey W. Sherman

See on IssueWire